Index
Module 15 • Shock & Hemodynamics
Shock Syndromes I
3%
⚡
Shock Syndromes I
Module 15 • 64 pages
Progress
3% • 2/64
1
Shock Syndromes I Gretchen L. Sacha, Pharm.D., FCC
2
Shock Syndromes I Shock Syndromes I Gretchen L. Sa
3
Shock Syndromes I Learning Objectives 1. Distingu
4
Shock Syndromes I determined that the patient is s
5
Shock Syndromes I 8. A 68-year-old woman (weight
6
Shock Syndromes I BPS Critical Care Pharmacy Exami
7
Shock Syndromes I I. INTRODUCTION A. Shock 1. S
8
Shock Syndromes I Value Equation (as applicable) N
9
Shock Syndromes I 6. SVR (also termed total perip
10
Shock Syndromes I 3. In general, less invasive de
11
Shock Syndromes I Device or Category Obtainable
12
Shock Syndromes I Device or Category Obtainable
13
Shock Syndromes I iii. Elevated lactate concentra
14
Shock Syndromes I 2. Regional tissue perfusion a.
15
Shock Syndromes I Patient Case 1. A 77-year-old m
16
Shock Syndromes I D. A patient’s history of prese
17
Shock Syndromes I 4. General goals of therapy inc
18
Shock Syndromes I d. The specific values of PPV a
19
Shock Syndromes I 10. The best dynamic marker of
20
Shock Syndromes I E. Adequate Do2 1. CO, Scvo2,
21
Shock Syndromes I V. AGENTS USED TO TREAT SHOCK –
22
Shock Syndromes I Table 4. Vasoactive Pharmacology
23
Shock Syndromes I 4. Inotropes exert a pharmacody
24
Shock Syndromes I b. Crystalloids vs. colloids i.
25
Shock Syndromes I iii. A large, double-blind, clu
26
Shock Syndromes I viii. Balanced crystalloid solu
27
Shock Syndromes I ii. Participants treated had mo
28
Shock Syndromes I Patient Case Questions 4 and 5 p
29
Shock Syndromes I B. Pathophysiology 1. Vasodila
30
Shock Syndromes I b. The potential offending agen
31
Shock Syndromes I VII. SEPSIS A. Introduction 1.
32
Shock Syndromes I C. Epidemiology and Social Dete
33
Shock Syndromes I Box 1. Pharmacologic-Related Sur
34
Shock Syndromes I Box 1. Pharmacologic-Related Sur
35
Shock Syndromes I 2. Early recognition and treatm
36
Shock Syndromes I (c) Australasian Resuscitation
37
Shock Syndromes I • Recent studies have evaluated
38
Shock Syndromes I iv. Given these findings, in a
39
Shock Syndromes I e. This care bundle has been ad
40
Shock Syndromes I Patient Case 6. A 56-year-old w
41
Shock Syndromes I the differences in the benefit w
42
Shock Syndromes I iv. Procalcitonin and other bio
43
Shock Syndromes I ii. A systematic review and fix
44
Shock Syndromes I c. Low-dose AVP (up to 0.03 uni
45
Shock Syndromes I (a) A study of patients with va
46
Shock Syndromes I iii. During a shortage of norep
47
Shock Syndromes I Patient Case 7. A 55-year-old m
48
Shock Syndromes I iv. The Activated Protein C and
49
Shock Syndromes I Patient Case 8. A 62-year-old w
50
Shock Syndromes I iv. Although the study did not
51
Shock Syndromes I (e) Initiation of inhaled nitri
52
Shock Syndromes I REFERENCES Introduction Huang YC
53
Shock Syndromes I shock. Crit Care Med. 2004;32(9)
54
Shock Syndromes I Puskarich MA, Trzeciak S, Shapir
55
Shock Syndromes I Myburgh JA, Finfer S, Bellomo R,
56
Shock Syndromes I Wood GC, Boucher AB, Johnson JL,
57
Shock Syndromes I Med. 2017;195(7):906-911. http
58
Shock Syndromes I Kumar A, Ellis P, Arabi Y, et al
59
Shock Syndromes I early septic shock. N Engl J Med
60
Shock Syndromes I vasodilatory shock: a randomized
61
Shock Syndromes I ANSWERS AND EXPLANATIONS TO PATI
62
Shock Syndromes I to the new definition (Answer B
63
Shock Syndromes I ANSWERS AND EXPLANATIONS TO SELF
64
Shock Syndromes I 6. Answer: D The patient has fe
Core Content
Shock Syndromes I
Gretchen L. Sacha
~1 min read
Module 15 of 20
2
/ 64
Shock Syndromes I
Shock Syndromes I
Gretchen L. Sacha, Pharm.D., FCCM, BCCCP
Cleveland Clinic
Cleveland, Ohio
HD Video Explanation — Synchronized with PDF
Starts at: minute 1
Open on YouTube
Previous
Page
/ 64
←
→
navigate
Space
next
Next